Major Prostate Cancer Trial: Short HT Best in Middle RiskMajor Prostate Cancer Trial: Short HT Best in Middle Risk
Investigators hypothesized that extending the period of neoadjuvant hormone therapy (HT) would improve outcomes. They were wrong. Medscape Medical News
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
More News: Cancer | Cancer & Oncology | Health | Hematology | Hormonal Therapy | Hormones | Neoadjuvant Therapy | Prostate Cancer